PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Biochem Biophys Res Commun. Author manuscript; available in PMC 2010 November 20.
Published in final edited form as:
PMCID: PMC2759846
NIHMSID: NIHMS144536

The Parkinson’s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites

Abstract

Mutations in Leucine-rich repeat kinase 2 (LRRK2) are a common cause of inherited Parkinson’s disease (PD). The protein is large and complex, but pathogenic mutations cluster in a region containing GTPase and kinase domains. LRRK2 can autophosphorylate in vitro within a dimer pair, although the significance of this reaction is unclear. Here, we mapped the sites of autophosphorylation within LRRK2 and found several potential phosphorylation sites within the GTPase domain. Using mass spectrometry, we found that Thr1343 is phosphorylated and, using kinase dead versions of LRRK2, show that this is an autophosphorylation site. However, we also find evidence for additional sites in the GTPase domain and in other regions of the protein suggesting that there may be multiple autophosphorylation sites within LRRK2. These data suggest that the kinase and GTPase activities of LRRK2 may exhibit complex autoregulatory interdependence.

Keywords: Parkinson’s disease, kinase, GTPase, autophosphorylation

Introduction

Protein kinases play key regulatory roles for many processes in cells, influencing signal transduction cascades by the phosphorylation of target proteins. As such, misregulated kinases are associated with many types of human disease. For example, activating mutations are a common and recurrent cause of diverse types of cancer [1]. Mutations are often found in the magnesium binding motif (consensus DY/FG) of the activation loop, a flexible region of many kinases that controls net activity.

Similar types of activating mutations in LRRK2 (leucine-rich repeat kinase 2), cause dominantly inherited form of Parkinson’s disease (PD) [2]. A very common mutation, G2019S, is found in the Mg2+ binding motif and increases kinase function [3]. However, LRRK2 is a complicated molecule that includes protein-protein interaction domains as well as a second catalytic region, the ROC (ras of complex proteins) domain, which is an active GTPase [4; 5; 6], and an adjacent COR (C-terminal of ROC) region that may regulate the ROC domain via dimerization [7]. Although there is some controversy, mutations in the ROC domain (R1441C/G/H) do not generally increase kinase activity [3] and are apparently instead associated with decreased GTPase activity [4; 5; 6; 8].

Several models have been proposed to reconcile these two different molecular effects of mutations in LRRK2. GTP binding to the ROC domain can modestly stimulate kinase activity [4; 9; 10; 11], suggesting that decreased GTPase activity might lead to enhanced kinase signaling. However, there is little evidence that mutations in the ROC domain increase kinase activity in the presence of GTP.

Understanding the effects of mutations in LRRK2 on kinase activity has been hampered by a lack of understanding of authentic substrates of the enzyme. Proposed substrates include moesin [12], 4EBP [13], MKK3/6 [14], β-tubulin [15] and α-synuclein [16] but none have been shown to be true in vivo, and pathogenic mutations do not consistently have increased activity towards any specific substrate. For example, Jaleel et al examined the effects of LRRK2 mutations on phosphorylation of a peptide derived from moesin (LRRKtide) and found that only G2019S caused a significant increase in kinase activity [12].

These considerations suggest either that kinase activity of LRRK2 is irrelevant for pathogenesis of PD or that current assays do not capture a pathological kinase activity. Regarding the first possibility, we have shown [17], and others have confirmed [18], that kinase activity contributes to toxic effects of mutant LRRK2 in vitro, even for pathogenic mutations outside of the kinase domain. This suggests that the kinase activity of LRRK2 is important either as an output of signaling or a modulator of another part of the protein. Potentially relevant to the second point, many assays have been performed using autophosphorylation of LRRK2 as a surrogate for activity in the absence of a known pathological substrate. Autophosphorylation of kinases is often seen in vitro, although there are examples where autophosphorylation is a physiologically relevant event. For example, ligand binding to dimeric receptor tyrosine kinases triggers autophosphorylation that leads to recruitment of additional protein partners and initiation of intracellular signaling cascades. In many cases [19], kinases phosphorylate their own kinase domains. LRRK2 forms dimers and full length LRRK2 can autophosphorylate within a dimer [20], although the isolated LRRK2 kinase domain can phosphorylate in trans [21].

Such data indicates that understanding autophosphorylation might be interesting in understanding the behavior of LRRK2. Therefore, in the current study we examined the sites of LRRK2 autophosphophorylation in vitro. Surprisingly, we found that LRRK2 autophosphorylates within the ROC/GTPase domain of the same protein, raising the possibility that complex autoregulation of LRRK2 may occur.

Materials and Methods

Mutagenesis

All point mutations were inserted into LRRK2 full length cDNA [17] or fragments using the Quick Change site-directed mutagenesis kit (Stratagene). Primers sequences are available upon request. Constructs were fully sequenced to confirm fidelity.

Recombinant proteins

ROC (amino acids 1333–1516), ROC-COR (1333–1845) and kinase (1887–2091) domains were cloned into pSKB3 vectors with hexa-histidine tags and expressed in E. coli. The kinase domain was co-expressed with two different molecular chaperones (trigger factor, C2; GroEL/ES, C3). All proteins were purified as described [8]. For N-terminal GST tags, ROC (1333–1516) was cloned into pGEX-5X1 (GE Life Sciences), expressed in E. coli, purified with glutathione sepharose beads (GE Life Sciences) and eluted with 10 mM glutathione in PBS (pH 8.0). ROC (1335–1548) was also cloned into pRSET-A with an N-terminal histidine tag. Proteins were expressed in E. coli, collected as inclusion bodies, resolubilized using 6M guanidinium hydrochloride, purified on Ni-TED affinity resin and refolded on the column using a GuHCl gradient. Proteins were eluted in 50 mM NaH2PO4, 300 mM NaCl, 0.1 mM DTT and 1% Empigen pH 8.0 with imidazole. Proteins displayed >95% purity by SDS-PAGE and Coomassie staining.

Recombinant LRRK2970–2527 with an N-terminal GST tag purified from insect cells was purchased from Invitrogen. LRRK21326–2527 was cloned into pFastBac1 (Invitrogen) with N-terminal Flag tag and C-terminal His tags and used to generate baculovirus with the Bac-to-Bac Expression system (Invitrogen). Sf9 cells were infected with viruses and harvested after 48 hours. Protein was purified by anti-Flag M2 affinity chromatography according to the manufacturer’s instructions (Sigma), confirmed by MALDI analysis and stored in 50 mM Tris (pH7.5), 150 mM NaCl, 10% glycerol, 0.01% Brij-35, 0.1 mg/ml Flag peptide at −80°C.

For mammalian expression, full length human LRRK2, the N-terminal region of LRRK2 (amino acids 1–1248), LRR (982–1280), ROC (1335–1548), COR (1550–1880), kinase (1880–2138) and WD40 (2150–2500) were cloned into the pCHMWS expression plasmid [22], incorporating an N-terminal 3×flag tag. HEK293T cells were transfected using Fugene and lysed after 48–72 hours in 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton, 10 % Glycerol and protease inhibitor cocktail (Roche). Lysates were cleared by centrifugation at 20,000 g for 10 minutes, pre-cleared with normal mouse IgG bound to agarose beads (Sigma), incubated for 3 h to 18 h with flagM2 bound to agarose beads (Sigma), washed with 25 mM Tris (pH 7.5), 400 mM NaCl, 1% Triton and rinsed in kinase buffer (25 mM Tris-HCl (pH 7.5), 5 mM beta-glycerophosphate, 2 mM dithiothreitol (DTT), 0.1 mM Na3VO4, 10 mM MgCl2), then eluted from beads with 3×flag peptide (Sigma).

Kinase assays

Recombinant domain proteins were incubated with recombinant GST tagged LRRK2970–2527 or recombinant full length 3×flag tagged LRRK2 in 40 µl kinase buffer containing 6 µCi of 33P-ATP (3000 Ci/mmol; Perkin Elmer) for 1 hour at 30°C. Reactions were terminated by adding 6× SDS loading buffer, loaded onto 4–20% SDS-PAGE gels (Biorad) and transferred onto Immobilon-P membranes (Millipore). Incorporated 33P-ATP was detected by autoradiography using a Storm 840 scanner (GE Healthcare). The same membranes were stained with Coomassie blue or Ponceau S (Sigma) or probed with anti-GST (GE Life Sciences), Flag M2 (Sigma) or DR4A/3EDD anti-LRRK2 [23] to confirm the presence of proteins. Densitometric analysis of the bands on the blot autoradiograms and immunoreactivity were performed using Aida Image Analyzer Software v4.0 (Raytest GmbH, Straubenhardt, Germany).

Autophosphorylation assays were performed using 30 µM LRRK21326–2527,1 µCi [γ-32P]ATP and 25 µM of ATP and incubated at RT for 0h or 17h. Reactions were stopped by adding Laemmli buffer and boiling the samples for 5 minutes. Samples were separated on a gradient 4–20% SDS-PAGE (BioRad). Gels were stained with coomassie brilliant blue, destained overnight, dried on 3 mm Whatman paper using a gel dryer (Biorad) and exposed to film to generate an autoradiogram.

Phosphopeptide identification

LRRK21326-2527 protein (50 µg) was digested using trypsin [24], and peptides were desalted using a C18 cartridge. Phosphopeptides were subjected to beta-elimination using d0 or d6 labeled DTT as the base for Michael addition, combined and enriched using Thiopropyl Sepharose 6B beads (GE Life Sciences). After extensive washing, peptides were eluted using 100 mM DTT and analyzed using a Thermo Finnigan FT-LTQ mass spectrometer. The peptides were identified through database search, and potential phosphorylated peptides were further verified by manual inspection of the raw MS and MS/MS spectra. Only those peptides that were first identified to be DTT labeled and also displayed as ion pairs, 2–3 Da apart, in the MS spectra were concluded to be authentic phosphopetides.

Selected reaction monitoring (SRM) analysis

To determine phosphorylation sites in LMIVGNTGSGK and DYHFVNATEESDALAK, all possible phosphorylated peptides were synthesized and analyzed using TSQ-Quantum to determine the peptide retention time and their fragmentation pattern. Phosphopeptides released from digestion of LRRK2 were then compared with these peptide standards.

Results

LRRK2 phosphorylates its isolated ROC/GTPase domain

To identify the site(s) of LRRK2 autophosphorylation, we screened different LRRK2 fragments as potential substrates for LRRK2 kinase activity. We used recombinant LRRK2970–2527 from an insect cell expression system that is highly active for autophosphorylation [25]. Approximately 25 nM of LRRK2970–2527 was used against ROC (1 µM), ROC-COR (0.2 µM) or kinase (1 µM; two different chaperones were used to maintain solubility) domains expressed in E coli. LRRK2970–2527 was able to phosphorylate the ROC fragment and the ROC-COR bidomain but not the kinase domain (Fig 1A). We also expressed and purified LRRK2 domains (LRRs, ROC, COR, Kinase and WD40) in HEK293T cells and found that LRRK2970–2527 can efficiently transfer a phosphate group to the ROC domain (Fig. 1B). The COR domain alone did not incorporate any detectable radiolabel, and we found only minor phosphorylation of the kinase, LRR and WD40 domains. These results suggest that the ROC domain is a major target of LRRK2 autophosphorylation activity.

Figure 1
LRRK2 phosphorylates the isolated LRRK2 ROC domain

To confirm this result with full-length protein, we used ~50 nM 3×flag-tagged wild-type, K1906M or G2019S LRRK2 from mammalian cells and ~2 µM of his-tagged ROC domain from E. coli. Wild-type LRRK2 efficiently phosphorylated ROC while the K1906M variant showed decreased activity (Fig. 1C). The G2019S mutant not only displayed increased autophosphorylation, but also higher ROC phosphorylation compared to wild-type (Fig. 1C). Collectively, these results suggest that LRRK2 can phosphorylate its own isolated ROC domain.

Mass spectrometry reveals multiple potential phosphosites

We next identified candidate phosphoacceptor sites within the ROC domain using 3µM of recombinant protein and 25 nM LRRK2970–2527 . To allow for the possibility that there may be additional sites outside of the ROC domain, we also performed similar assays with 200 nM LRRK2970–2527 alone. In both experiments, we analyzed resultant digested and enriched phosphopeptides by liquid chromatography and tandem mass spectrometry (LC-MS/MS; Table 1).

Table 1
Identification of possible phosphosites in recombinant LRRK2

Seven potential phosphosites were found in either LRRK2970–2527 or isolated ROC. Only threonine or serine but not tyrosine residues were identified. Among the peptides located within ROC, three were recovered mutliple times; a peptide phosphorylated at T1343/S1345 (recovered 20 times from ROC and 7 times from LRRK2970–2527); the tandem site T1348/T1349 (10 times from ROC, twice from LRRK2970–2527) and T1491 (10 times from ROC). Two peptides were identified outside of the ROC domain using LRRK2970–2527, one peptide located in the LRR domain containing T1024/S1025 and another peptide in the kinase domain at position T2031/S2032, each recovered once.

Confirmation of T1343 as an autophosphorylation site

In several of the above peptides, there were mutliple Ser/Thr residues. We used two independent techniques to attempt to confirm the authentic sites within each peptide. We first repeated the above experiments with a slightly different LRRK2 recombinant construct expressed in Sf2 cells, LRRK21326–2527 , that is also highly active [12]. We isolated four peptides that overlapped with those found in the above experiments in the ROC domain and, using SRM analysis (Figure 2), were able to unambiguously identify T1343 and T1491 as phosphosites (Table 2). We also found evidence of phosphorylation at T2031 in the kinase domain as well as minor sites in the COR and WD40 domains.

Figure 2
Identification of the phosphorylation site in LRRK21337–1347 using selected reaction monitoring
Table 2
Selective reaction monitoring (SRM) identification of phosphorylation sites in LRRK21337–1347

To attempt to confirm this data, we mutagenized all the candidate residues to alanine in a substrate construct. Recombinant GST-ROC proteins (~ 0.5 µM) were then used as substrates for phosphorylation by full-length 3×flag-LRRK2 (Figure 3). Quantitation of the amount of radiolabeled phosphate transferred to each GST-ROC mutant shows that T1343A had ~ 50% phosphorylation of wild-type.

Figure 3
Confirmation of possible phosphorylation sites by mutagenesis

We next quantified the proportion of peptides that were phosphorylated for the two most promising candidate sites, T1343 and T1491. We used recombinant LRRK21326–2527 and compared kinase dead (D2017A) with the activating G2019S mutant under basal conditions and under conditions of extended incubation of kinase reactions (Table 3). Neither T1343 nor T1491 were phosphorylated in the kinase dead construct. Consistent with the higher number of recovered peptides for T1343 in Table 1, the proportion of peptide phosphorylated at T1343 was higher (~23%) than for T1491 (~6%). However, neither site was completely phosphorylated nor was the proportion of phosphopeptides increased with longer incubation times (Table 3). We did find increased 32P incorporation into WT or G2019S, but not kinase dead, LRRK2 after similar 17h incubations (Supplementary figure S1). Collectively, these results support the identification of T1343 as a site for autophosphorylation of LRRK2 but suggest that additional sites exist.

Table 3
T1343 and T1491 represent autophosphorylation sites

Discussion

Several mutations in the complex multi-domain kinase LRRK2 are linked to PD but the mechanism(s) by which they affect protein function are poorly understood. Data on kinase activity has been controversial for all mutations apart from G2019S, which is activating. However, our incomplete understanding of the normal physiological substrates of LRRK2 complicates interpretation of this data. As several laboratories have used autophosphorylation as a proxy for kinase activity, the aim of the current study was to identify the autophophosphorylation sites of LRRK2.

We expected that we might see evidence of autophosphorylation within the kinase domain of LRRK2, as this would be a likely regulatory site. However, we found only minor evidence for phosphorylation of one residue, T2031, in this domain. In contrast, several lines of evidence suggest that residues in the GTPase/ROC domain of LRRK2 are autophosphorylated.

Of the sites identified with the ROC domain, the most consistent candidate is T1343. Previous data has shown that a ras-like T1343G mutation in full length LRRK2 has decreased kinase activity when combined with R1398Q [8]. T1348N, which converts LRRK2 to a GTP deficient version, also decreases kinase activity [9]. One interpretation of these results is that they reflect a requirement of guanine nucleotides for kinase activity but they may also represent loss of autophosphorylation of the protein when T1343 is mutated. This may explain why such mutations have a dramatic effect, decreasing kinase activity by about 50% when addition of GDP to immunoprecipated LRRK2 has no effect on kinase activity [18].

Compared to T1343, T1491 appears to be a relatively minor site based on quantitation by mass-spectrometry and from experiments showing that T1491A in GST-ROC domain has a minimal effect on overall phosphorylation. Another minor site is at T2031, which we have previously shown can impact kinase activity as expected for an activation loop residue [20].

Phosphorylation of the ROC domain suggests that autoregulation within LRRK2, which has previously been proposed to be of the kinase domain by the ROC domain, might occur from kinase activity to the GTP binding region. One possibility is that phosphorylation of one or more threonine residues may alter GTPase activity. A hyperactive kinase mutation such as G2019S would be predicted to decrease GTPase activity and would be functionally similar to R1441 mutations in the ROC domain that have lower inherent GTPase activity [4; 5; 6; 8]. If correct, then kinase inhibition, which has been suggested as a possible therapeutic approach for LRRK2 PD [26] would likely be effective in maintaining GTPase activity by inhibiting such repression.

Overall, our results identify two novel sites for autophosphorylation of LRRK2. It is of interest that these sites are within the other enzymatic domain of LRRK2, the ROC/GTPase region as this suggests a complex autoregulation of LRRK2. These sites now need to be confirmed in vivo, perhaps using phosphospecific antibodies that are yet to be developed. However, several considerations suggest that T1343 and T1491 are not the only two autophosphorylation sites within LRRK2, including that we did not find quantitative changes at either T1343 or T1491 under conditions where autophosphorylation proceeds further. Further work is required to identify these additional sites in future experiments.

Supplementary Material

01

Acknowledgements

This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (AG000948-01) and the National Institute of Neurological Diseases and Stroke and by the Flemish Fund for Scientific Research FWO Vlaanderen (G.0406.06, G. 0666.09). The National Institute of Neurological Diseases and Stroke also supported this work by grant NS062287 to J.D. RVC is a research assistant and J-M. T. is a postdoctoral researcher of the Flemish fund for scientific research (FWO). J-M. T is a Fulbright research scholar. The authors thank Evy Lobbestael and Fangye Gao for technical assistance.

Abbreviations

COR
C-terminal of ROC
LRRK2
leucine-rich repeat kinase 2
PD
Parkinson’s disease
ROC
ras of complex proteins

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153–158. [PMC free article] [PubMed]
2. Paisan-Ruiz C. LRRK2 gene variation and its contribution to Parkinson disease. Hum Mutat. 2009;30:1153–1160. [PubMed]
3. Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro. 2009;1 [PMC free article] [PubMed]
4. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res. 2007;313:3658–3670. [PMC free article] [PubMed]
5. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun. 2007;357:668–671. [PMC free article] [PubMed]
6. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem. 2007;103:238–247. [PMC free article] [PubMed]
7. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J. 2008;27:2239–2249. [PubMed]
8. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A. 2008;105:1499–1504. [PubMed]
9. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, Iwatsubo T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry. 2007;46:1380–1388. [PubMed]
10. Korr D, Toschi L, Donner P, Pohlenz HD, Kreft B, Weiss B. LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal. 2006;18:910–920. [PubMed]
11. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet. 2007;16:223–232. [PubMed]
12. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J. 2007;405:307–317. [PubMed]
13. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008;27:2432–2443. [PubMed]
14. Gloeckner CJ, Schumacher A, Boldt K, Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem. 2009;109:959–968. [PubMed]
15. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in Parkinsonian neurodegeneration? J Neurochem. 2009 [PubMed]
16. Qing H, Wong W, McGeer EG, McGeer PL. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun. 2009;387:149–152. [PubMed]
17. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis. 2006;23:329–341. [PubMed]
18. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006;9:1231–1233. [PubMed]
19. Smith JA, Francis SH, Corbin JD. Autophosphorylation: a salient feature of protein kinases. Mol Cell Biochem. 1993;127–128:51–70. [PubMed]
20. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A, Thomas KJ, Baekelandt V, Cookson MR. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem. 2008;283:16906–16914. [PubMed]
21. Luzon-Toro B, Rubio de la Torre E, Delgado A, Perez-Tur J, Hilfiker S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet. 2007;16:2031–2039. [PubMed]
22. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, Debyser Z. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum.Gene Ther. 2002;13:841–853. [PubMed]
23. Taymans JM, Van den Haute C, Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J.Neurochem. 2006;98:951–961. [PubMed]
24. Zhen Y, Xu N, Richardson B, Becklin R, Savage JR, Blake K, Peltier JM. Development of an LC-MALDI method for the analysis of protein complexes. J Am Soc Mass Spectrom. 2004;15:803–822. [PubMed]
25. Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungaliya P, Brown EL, Reinhart PH, Somberg R, Hirst WD, Riddle SM, Braithwaite SP. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. FEBS J. 2009;276:466–478. [PubMed]
26. Reichling LJ, Riddle SM. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochem Biophys Res Commun. 2009;384:255–258. [PubMed]